Co-occurrence of hyperleukocytosis and elevated fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia

Int J Hematol. 2016 Nov;104(5):612-620. doi: 10.1007/s12185-016-2072-5. Epub 2016 Jul 25.

Abstract

Early intracranial hemorrhage (eICH) is a potentially fatal complication of acute leukemia. We analyzed risk factors for eICH in patients with de novo acute leukemia. Ninety-one de novo acute leukemia patients at our institution between September 2003 and June 2014 were included. Of the 91 patients, eight (8.8 %) and 83 were included in the eICH and non-eICH groups, respectively. Univariate analysis demonstrated that white blood cell (WBC) count (P = 0.018), fibrin-fibrinogen degradation product (FDP) level (P = 0.0075), co-occurrence of WBC ≥50,000/µl and FDP level >40 µg/ml (P < 0.001), and fever (P = 0.248) were all significant predictors of eICH at the 0.25 level. In a subsequent multivariate analysis involving these parameters, only the combination of hyperleukocytosis and elevated FDP levels was found to be significant at the 0.05 level. A significant difference in the duration of the overall survival (OS) period was detected between patients that did and did not exhibit the combination of hyperleukocytosis and elevated FDP levels (P < 0.001). Co-occurrence of hyperleukocytosis and elevated FDP levels is a significant risk factor for eICH in patients with de novo acute leukemia and has a significant adverse affect on OS.

Keywords: Acute leukemia; Disseminated intravascular coagulation; Early intracranial hemorrhage; Fibrin–fibrinogen degradation product; Hyperleukocytosis.

MeSH terms

  • Acute Disease
  • Adult
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Intracranial Hemorrhages / blood
  • Intracranial Hemorrhages / diagnosis
  • Intracranial Hemorrhages / etiology*
  • Leukemia / complications*
  • Leukemia / mortality
  • Leukocyte Count
  • Leukocytosis*
  • Middle Aged
  • Risk Factors
  • Survival Rate

Substances

  • Fibrin Fibrinogen Degradation Products